GABRR1 — GABA-A Receptor Rho1 Subunit

GABRR1 — GABA-A Receptor Rho1 Subunit

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GABRR1 — GABA-A Receptor Rho1 Subunit</th>
</tr>
<tr>
<td class="label">Agonist</td>
<td>GABA, CACA</td>
</tr>
<tr>
<td class="label">Antagonist</td>
<td>TPMPA, PTT</td>
</tr>
<tr>
<td class="label">Bicuculline sensitivity</td>
<td>No</td>
</tr>
<tr>
<td class="label">Benzodiazepine sensitivity</td>
<td>No</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Type</td>
</tr>
<tr>
<td class="label">rs1913510</td>
<td>SNP</td>
</tr>
<tr>
<td class="label">rs1893532</td>
<td>SNP</td>
</tr>
<tr>
<td class="label">rs1057396</td>
<td>SNP</td>
</tr>
<tr>
<td class="label">rs832753</td>
<td>SNP</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GABRR2 (rho2)</td>
<td>Heteromeric assembly</td>
</tr>
<tr>
<td class="label">GABRR3 (rho3)</td>
<td>Heteromeric assembly</td>
</tr>
<tr>
<td class="label">GABAC1</td>
<td>Co-assembly</td>
</tr>
<tr>
<td class="label">VILIP-1</td>
<td>Physical binding</td>
</tr>
<tr>
<td class="label">GRIP1</td>
<td>Scaffold interaction</td>
</tr>
<tr>
<td class="label">PSD-95</td>
<td>PSD binding</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Expression Change</td>
</tr>
<tr>
<td class="label">AD hippocampus</td>
<td>Downregulated</td>
</tr>
<tr>

GABRR1 — GABA-A Receptor Rho1 Subunit

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GABRR1 — GABA-A Receptor Rho1 Subunit</th>
</tr>
<tr>
<td class="label">Agonist</td>
<td>GABA, CACA</td>
</tr>
<tr>
<td class="label">Antagonist</td>
<td>TPMPA, PTT</td>
</tr>
<tr>
<td class="label">Bicuculline sensitivity</td>
<td>No</td>
</tr>
<tr>
<td class="label">Benzodiazepine sensitivity</td>
<td>No</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Type</td>
</tr>
<tr>
<td class="label">rs1913510</td>
<td>SNP</td>
</tr>
<tr>
<td class="label">rs1893532</td>
<td>SNP</td>
</tr>
<tr>
<td class="label">rs1057396</td>
<td>SNP</td>
</tr>
<tr>
<td class="label">rs832753</td>
<td>SNP</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GABRR2 (rho2)</td>
<td>Heteromeric assembly</td>
</tr>
<tr>
<td class="label">GABRR3 (rho3)</td>
<td>Heteromeric assembly</td>
</tr>
<tr>
<td class="label">GABAC1</td>
<td>Co-assembly</td>
</tr>
<tr>
<td class="label">VILIP-1</td>
<td>Physical binding</td>
</tr>
<tr>
<td class="label">GRIP1</td>
<td>Scaffold interaction</td>
</tr>
<tr>
<td class="label">PSD-95</td>
<td>PSD binding</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Expression Change</td>
</tr>
<tr>
<td class="label">AD hippocampus</td>
<td>Downregulated</td>
</tr>
<tr>
<td class="label">PD substantia nigra</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">Epilepsy tissue</td>
<td>Altered splicing</td>
</tr>
<tr>
<td class="label">Aging brain</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">Drug/Compound</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">TPMPA</td>
<td>Variable response</td>
</tr>
<tr>
<td class="label">Baclofen</td>
<td>Altered sensitivity</td>
</tr>
<tr>
<td class="label">GABA derivatives</td>
<td>Differential response</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Application</td>
</tr>
<tr>
<td class="label">qPCR</td>
<td>mRNA expression</td>
</tr>
<tr>
<td class="label">Western blot</td>
<td>Protein levels</td>
</tr>
<tr>
<td class="label">IHC</td>
<td>Localization</td>
</tr>
<tr>
<td class="label">Radioligand binding</td>
<td>Receptor density</td>
</tr>
<tr>
<td class="label">Electrophysiology</td>
<td>Function</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

GABRR1 (GABA-A Receptor Rho1 Subunit) encodes the ρ1 (rho1) subunit of GABA receptors, originally termed the GABA-C receptor[@enz2017]. The rho1 subunit forms homomeric or heteromeric GABA-gated chloride channels that are structurally similar to GABA-A receptors but pharmacologically distinct. This gene is located at chromosome 9q33.1 and is expressed in various brain regions including the retina, spinal cord, suprachiasmatic nucleus, and substantia nigra.

Molecular Biology

Protein Structure

The GABRR1 protein (UniProt: P28476) contains:

• Extracellular N-terminus: Contains the GABA binding site
• Transmembrane domains: Four helical transmembrane segments (TM1-4)
• Intracellular loop: Between TM3 and TM4, involved in phosphorylation
• C-terminal region: Mediates subunit assembly and trafficking

Expression Pattern

GABRR1 shows distinctive expression in the nervous system:

• Retina: Rod bipolar cells, cone bipolar cells, horizontal cells[@kourennyi2016]
• Spinal cord: Dorsal horn neurons
• Suprachiasmatic nucleus: Circadian rhythm regulation[@ehlen2017]
• Superior colliculus
• Olfactory bulb
• Substantia nigra pars reticulata: Modulation of motor circuits
• Hippocampus: Synaptic plasticity and memory

Role in Neurodegenerative Diseases

Alzheimer's Disease

GABRR1 expression is altered in Alzheimer's disease (AD) pathophysiology. Research has shown that:

Parkinson's Disease

In Parkinson's disease (PD), GABRR1 is implicated through:

Other Neurodegenerative Conditions

• Epilepsy: GABRR1 variants are associated with juvenile myoclonic epilepsy and generalized epilepsy syndromes[@maljevic2018]
• Age-related cognitive decline: Genetic polymorphisms in GABRR1 correlate with cognitive decline in aging populations[@nakamura2018]
• Neuroinflammation: GABA(C) receptors on microglia modulate inflammatory responses[@sato2019]

Signaling Mechanisms

Receptor Pharmacology

GABRR1-containing receptors exhibit unique pharmacological properties:

Signal Transduction

GABA(C) receptor activation leads to:

Therapeutic Implications

Drug Development

GABRR1 represents a potential therapeutic target for:

Gene Therapy Approaches

Recent research has explored:

• Viral vector delivery of GABRR1 for restoring GABAergic function
• CRISPR-based approaches for correcting pathogenic variants
• RNA-based therapeutics targeting GABRR1 expression

Common Variants and Genetic Studies

Genome-wide association studies have identified GABRR1 variants associated with:

• Epilepsy susceptibility
• Sleep disorders
• Cognitive function in aging
• Response to GABAergic drugs

Research Directions

Current Areas of Investigation

Future Perspectives

• Development of subtype-selective GABA(C) receptor modulators
• Personalized medicine approaches based on GABRR1 genotype
• Combination therapies targeting multiple GABA receptor subtypes

Animal Models and Experimental Systems

Mouse Models

GABRR1 knockout mice (Gabrr1-/-) have been generated and characterized:

Behavioral phenotypes:

• Increased locomotor activity in open field tests
• Altered circadian rhythm patterns
• Enhanced seizure susceptibility
• Memory consolidation deficits in Morris water maze

• Reduced GABA-evoked currents in retinal bipolar cells
• Altered inhibitory synaptic transmission in the hippocampus
• Changes in neuronal excitability in the substantia nigra pars reticulata
• Dysregulated dopamine release in basal ganglia circuits

Zebrafish Models

Zebrafish gabrr1 morphants show:

• Developmental abnormalities in retinal patterning
• Altered GABAergic neuron migration
• Motor circuit formation defects

Cell Culture Systems

Expression systems:

• HEK293T cells for receptor characterization
• Xenopus oocytes for electrophysiological studies
• SH-SY5Y neuroblastoma cell lines for disease modeling

• Primary cortical neurons from wild-type and knockout mice
• Retinal bipolar cell cultures
• Midbrain dopaminergic neuron cultures

Protein Interactions and Network

Direct Protein Interactions

GABRR1 interacts with several proteins:

Signaling Network Integration

GABRR1 participates in several signaling networks:

• GABAergic signaling: Primary receptor for inhibitory transmission
• Dopaminergic modulation: Cross-talk with D1/D2 receptor pathways
• Circadian clock integration: SCN signaling
• Motor control circuits: Basal ganglia output modulation

Differential Expression in Disease

GABRR1 expression is altered in several disease states:

Clinical Studies and Trials

Biomarker Studies

GABRR1 has been investigated as a potential biomarker:

Cerebrospinal fluid studies:

• GABRR1 protein levels measurable in CSF
• Correlations with disease severity
• Potential for disease progression monitoring

• Variant associations with disease risk
• Pharmacogenomic responses to GABAergic drugs

Clinical Trials Targeting GABA(C) Receptors

Several clinical approaches have been investigated:

Observational Studies

• Longitudinal studies of GABRR1 variants and cognitive decline
• Imaging studies correlating receptor density with brain function
• Post-mortem brain studies in AD and PD

Pharmacogenomics

Drug Responses

GABRR1 variants affect responses to:

Personalized Medicine Potential

• Genotype-guided therapy selection
• Dose optimization based on receptor function
• Combination therapy considerations

Research Methods

Detection Methods

Manipulation Methods

• CRISPR-Cas9 knockout
• siRNA knockdown
• Overexpression constructs
• Cre-lox conditional knockout

Conclusion and Future Perspectives

GABRR1 represents a unique GABA receptor subtype with distinctive pharmacological properties and brain distribution. While traditionally considered a retinal receptor, increasing evidence supports important roles in various brain regions and neurodegenerative diseases. The development of selective GABA(C) receptor modulators offers therapeutic opportunities for AD, PD, and other neurological conditions. However, challenges remain in achieving brain-penetrant, subtype-selective compounds and understanding the full spectrum of GABRR1 functions in the human brain. Future research should focus on:

Cross-References

• [GABRR2](/genes/gabrr2) — GABA-A receptor rho2 subunit
• [GABRR3](/genes/gabrr3) — GABA-A receptor rho3 subunit
• [GABA Signaling in Neurodegeneration](/mechanisms/gaba-signaling)
• [Suprachiasmatic Nucleus and Circadian Rhythms](/brain-regions/suprachiasmatic-nucleus)
• [Substantia Nigra Pars Reticulata](/brain-regions/substantia-nigra)
• [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease)
• [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease)

External Links

• [NCBI Gene: GABRR1](https://www.ncbi.nlm.nih.gov/gene/2567)
• [UniProt: GABRR1](https://www.uniprot.org/uniprot/P28476)
• [IUPHAR: GABAρ1 receptor](https://www.guidetopharmacology.org/graphql/receptor/GPCR:2052)
• [Ensembl: GABRR1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000146228)
• [OMIM: GABRR1](https://www.omim.org/entry/137161)